Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety

BACKGROUND: Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP). METHODS AND RESULTS: Retrospective cohort study of patients taking QDay lisinopril and losartan who experienced a dose-doubling (index date)....

Descripción completa

Detalles Bibliográficos
Autores principales: Derington, Catherine G., King, Jordan B., Delate, Thomas, Botts, Sheila R., Kroehl, Miranda, Kao, David P., Trinkley, Katy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714357/
https://www.ncbi.nlm.nih.gov/pubmed/33270787
http://dx.doi.org/10.1371/journal.pone.0243371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714357/
https://www.ncbi.nlm.nih.gov/pubmed/33270787
http://dx.doi.org/10.1371/journal.pone.0243371

Ejemplares similares